CVRx Inc (CVRX) Peer Comparison

$3.04

$-0.23 (-7.03%)

As on 27-Aug-2026 16:28EDT

Market cap

$76 Mln

Revenue (TTM)

$61 Mln

P/E Ratio

--

P/B Ratio

3.8

Div. Yield

0 %

Edit

	CVRx Inc (CVRX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Market cap ($ Mln)	76	12,753	10,906	9,762	10,222
Revenue ($ Mln)	61	1,505	613	2,589	785
Net Profit ($ Mln)	-51.97	160.59	-188.05	222.40	41.54
Net Margin (%)	-84.93	10.67	-30.68	8.59	5.29
RoE (%)	-175.34	10.86	-28.10	3.04	1.97
Price to Earnings	--	79.35	--	44.47	251.57
Price-To-Book	3.77	8.41	16.38	1.26	4.84

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	CVRx Inc (CVRX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Operating Revenue	61.19	1,504.87	612.84	2,589.30	785.10
Cost of Revenue	8.20	483.98	127.96	1,245.50	384.30
Gross Profit	48.34	942.44	393.22	1,343.60	347.62
Operating Expenses	101.63	833.56	565.37	1,108.90	335.50
Operating Profit (EBIT)	-48.64	187.34	-80.49	235.00	65.30
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-51.97	203.83	-192.83	350.40	52.15
Provision for Tax	-0.01	43.24	-4.79	128.00	10.61
Profit after Tax (Net Income)	-51.97	160.59	-188.05	222.40	41.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	CVRx Inc (CVRX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Shareholder's Funds	19.95	1,530.77	682.49	7,173.90	2,112.03
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	61.21	210.18	135.71	2,116.80	705.49
Current Liabilities	11.12	233.78	102.33	961.30	132.66
Total Liabilities	104.79	1,826.52	893.49	10,576.50	2,949.70

Assets ($ Mln)

	CVRx Inc (CVRX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Non-Current Assets	2.80	630.60	404.74	7,231.50	1,749.63
Current Assets	89.49	1,344.12	515.78	3,020.50	1,200.55
Total Assets	104.79	1,826.52	893.49	10,576.50	2,949.70
Total Debt*	59.39	212.71	102.84	1,203.70	690.94
Net Current Assets	78.36	1,110.35	413.45	2,059.20	1,067.90

Cashflow ($ Mln)

	CVRx Inc (CVRX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Cash From Operating Activities	-40.17	238.66	-46.34	532.20	117.42
Cash Flow from Investing Activities	-0.58	-404.59	-77.61	-189.70	-298.47
Cash from Financing Activities	10.52	26.53	11.89	-283.20	-15.21
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	CVRx Inc (CVRX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
ROCE (%)	-50.38	11.76	-22.53	8.98	1.79
ROE (%)	-175.34	10.86	-28.10	3.04	1.97
ROA (%)	-44.67	7.95	-18.00	2.02	1.36
EBIT Margin (%)	-75.09	13.63	-30.58	-5.99	9.87
Net Margin (%)	-84.93	10.67	-30.68	8.59	5.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	CVRx Inc (CVRX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Revenue Growth (%)	11.96	17.55	41.55	1.37	16.49
EBIT Growth (%)	1.98	17.49	-116.42	-131.06	920.91
Net Profit Growth (%)	0.54	8.72	-102.66	-30.32	400.42
EPS Growth (%)	7.89	8.12	-96.88	-29.66	394.30
Book Value Growth (%)	-66.14	17.33	-12.65	2.19	2.16

Valuation Ratios

	CVRx Inc (CVRX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Price / Earnings	-3.49	68.93	-34.59	--	189.42
Price / Book Value	4.73	8.58	9.90	--	4.40
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-3.45	53.25	-43.50	--	55.90
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	CVRx Inc (CVRX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debt to Equity	2.94	0.00	0.00	0.11	0.26
Short term debt to equity ratio	0.02	0.01	0.00	0.06	0.01
Current Ratio	8.04	5.75	5.04	3.14	9.05
Quick Ratio	6.87	3.86	4.46	2.33	7.64
Interest Coverage	-7.62	157.91	-38.31	8.18	3.36

Operating Efficiency Ratios

	CVRx Inc (CVRX)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debtors to sales (%)	15.36	12.65	22.67	17.06	20.09
Asset Turnover	0.53	0.74	0.59	0.24	0.26
Receivable days	64.26	46.54	60.95	65.39	72.41
Inventory Days	534.23	331.92	193.84	221.09	146.53
Payable days	140.96	26.16	60.19	37.02	29.05
Cash Conversion Cycle	457.52	352.30	194.60	249.46	189.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly